Capstone Investment Advisors LLC purchased a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 13,066 shares of the company’s stock, valued at approximately $48,000.
Other hedge funds have also recently made changes to their positions in the company. Anfield Capital Management LLC bought a new position in Zentalis Pharmaceuticals in the second quarter worth about $40,000. Aigen Investment Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $41,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after acquiring an additional 5,333 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Zentalis Pharmaceuticals during the second quarter valued at approximately $58,000. Finally, Algert Global LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $78,000.
Zentalis Pharmaceuticals Stock Down 0.6 %
Zentalis Pharmaceuticals stock opened at $3.61 on Monday. The stock has a 50-day moving average price of $3.36 and a 200 day moving average price of $4.82. The company has a market capitalization of $257.27 million, a price-to-earnings ratio of -1.45 and a beta of 1.74. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.66 and a 52 week high of $18.07.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on ZNTL. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.00.
View Our Latest Report on ZNTL
Zentalis Pharmaceuticals Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Recommended Stories
- Five stocks we like better than Zentalis Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- What Does a Stock Split Mean?
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report).
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.